Enliven Therapeutics, Inc.·4

Sep 25, 7:44 PM ET

Lyssikatos Joseph P 4

4 · Enliven Therapeutics, Inc. · Filed Sep 25, 2025

Insider Transaction Report

Form 4
Period: 2025-09-23
Lyssikatos Joseph P
CHIEF SCIENTIFIC OFFICER
Transactions
  • Sale

    Common Stock

    2025-09-23$20.03/sh1,500$30,045931,688 total(indirect: See footnote)
Footnotes (2)
  • [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.
  • [F2]The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.

Documents

1 file
  • 4
    form4-09252025_110942.xmlPrimary